Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Milsing d.o.o. |
---|---|
Information provided by: | Milsing d.o.o. |
ClinicalTrials.gov Identifier: | NCT00446485 |
The purpose of the study is to determine weather Ginkgo biloba standardized extract (24% ginkoflavonoglicozides and 6% terpenes) is effective in treatment of cognitive and concentration impairment
Condition | Intervention | Phase |
---|---|---|
Mild Cognitive Impairment Cerebrovascular Insufficiency |
Drug: Ginkgo biloba standardized extract 24/6 Drug: Ginkgo Biloba standardized extract 24/6 Drug: placebo |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Efficacy and Safety of Ginkgo Biloba Standardized Extract (24% Ginkoflavonoglicozides and 6% Terpenes) in Treatment of Mild Cognitive and Concentration Impairment |
Estimated Enrollment: | 90 |
Study Start Date: | May 2007 |
Estimated Study Completion Date: | August 2008 |
Estimated Primary Completion Date: | August 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
Ginkgo Biloba standardized extract 24/6
|
Drug: Ginkgo biloba standardized extract 24/6
tablets, 120 mg/day (60 mg two times daily) during 6 months
Drug: Ginkgo Biloba standardized extract 24/6
tablets, 60 mg/day during 6 months
|
3: Placebo Comparator
placebo
|
Drug: placebo
placebo during 6 months
|
Inclusion criteria is cerebrovascular insufficiency MNSE>20. 90 patients are divided into three groups randomly. First group is being administered 120 mg ginkgo biloba extract, second group 60 mg of the extract and the third group has being administered placebo during the period of 6 months. Methods used for evaluation are SCAG, MMSE, MDRS, VFT, CGI, TCD and color Doppler of carotid arteries. Methods used for follow up safety include: routine blood tests, biochemical tests, neurologic and physical examination, vital signs and ECG.
Ages Eligible for Study: | 50 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Vida Demarin, MD, PhD | 00385 1 3787740 | vida.demarin@zg.t-com.hr |
Contact: Zlatko Trkanjec, MD, PhD | 00385 1 3787169 | ztrkanj@kbsm.hr |
Croatia | |
University Department of Neurology, Sestre milosrdnice University Hospital, Vinogradska 29 | Recruiting |
Zagreb, Croatia, 10000 | |
Contact: Vida Demarin, MD PHD 00385 1 3787740 vida.demarin@zg.t-com.hr | |
Contact: Zlatko Trkanjec, MD PHD 00385 1 3787169 ztrkanj@kbsm.hr | |
Sub-Investigator: Marijana Lisak, MD | |
Sub-Investigator: Sandra Morovic, MD | |
Sub-Investigator: Iris Zavoreo, MD | |
Sub-Investigator: Miljenka Jelena Kesić, MD | |
Sub-Investigator: Irena Martinic Popovic, MD | |
Sub-Investigator: Mislav Budisic, MD | |
Sub-Investigator: Jelena Bosnjak, MD | |
Sub-Investigator: Sonja Antic, MD |
Principal Investigator: | Vida Demarin, MD PHD | University Department of Neurology, Sestre milosrdnice University Hospital, Vinogradska 29, HR-10000 Zagreb, Croatia |
Responsible Party: | Sestra Milosrdnice University Hospital, Zagreb ( Vida Demarin MD PHD ) |
Study ID Numbers: | MIL-001 |
Study First Received: | March 12, 2007 |
Last Updated: | January 4, 2008 |
ClinicalTrials.gov Identifier: | NCT00446485 |
Health Authority: | Republic of Croatia: Ethic Committee of Sestre milosrdnice University Hospital |
ginkgo biloba cerebrovascular insufficiency mild cognitive impairment concentration impairment |
Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Vascular Diseases Central Nervous System Diseases Dementia |
Brain Diseases Cerebrovascular Disorders Cognition Disorders Delirium |
Nervous System Diseases Cardiovascular Diseases |